What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature.
about
Lifestyle changes for treating psoriasisAggression in autism spectrum disorder: presentation and treatment optionsQuality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003-2011.Health-related quality of life worsens disproportionately to objective signs of psoriasis after withdrawal of adalimumab therapy.Oral granulated Chinese herbal medicine (YXBCM01) plus topical calcipotriol for psoriasis vulgaris: study protocol for a double-blind, randomized placebo controlled trial.Patient satisfaction with treatments for moderate-to-severe plaque psoriasis in clinical practiceHealth related quality of life in patients with actinic keratosis--an observational study of patients treated in dermatology specialist care in Denmark.Physical and mental impact of psoriasis severity as measured by the compact Short Form-12 Health Survey (SF-12) quality of life tool.Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment.Validation of a new tool to assess health-related quality of life in psoriasis: the PSO-LIFE questionnaire.Reliability and validity of the Chinese version of the Psoriasis Disability Index (PDI) in Chinese patients with psoriasisPsoriasis: correlation between severity index (PASI) and quality of life index (DLQI) in patients assessed before and after systemic treatment.Assessing adherence factors in patients under topical treatment: development of the Topical Therapy Adherence Questionnaire (TTAQ).What's new in psoriasis? An analysis of guidelines and systematic reviews published in 2009-2010.Disease-syndrome combination clinical study of psoriasis: present status, advantages, and prospects.Application of the dermatology life quality index in clinical trials of biologics for psoriasis.Etanercept provides an effective, safe and flexible short- and long-term treatment regimen for moderate-to-severe psoriasis: a systematic review of current evidence.The burden of moderate to severe psoriasis: an overview.Treatment goals for moderate to severe psoriasis: an Australian consensus.PASI90 response: the new standard in therapeutic efficacy for psoriasis.Patient-reported outcome measures in psoriasis: the good, the bad and the missing!Consensus document on the evaluation and treatment of moderate-to-severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology.A European subset analysis from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis shows country-specific features: results from psoriasis patients in Spain.Moderate to severe psoriasis patients' subjective future expectations regarding health-related quality of life and longevity.Management of the psychological comorbidities of dermatological conditions: practitioners' guidelines.Development, validation, and initial results of the Angioedema Activity Score.EQ-5D health utilities: exploring ways to improve upon responsiveness in psoriasis.Register-Based Evaluation of Relative Effectiveness of New Therapies: Biologics Versus Conventional Agents in Treatment of Psoriasis in Sweden.Comparison of the paper-based and electronic versions of the Dermatology Life Quality Index: evidence of equivalence.Psoriasis: Epidemiology, clinical features, co-morbidities, and clinical scoring.Comparison of three methods for measuring psoriasis severity in clinical studies (Part 2 of 2): use of quality of life to assess construct validity of the Lattice System Physician's Global Assessment, Psoriasis Area and Severity Index and Static PhyApremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial.Psychometric properties of the Chinese version of Dermatology Life Quality Index (DLQI) in 851 Chinese patients with psoriasis.Comparison of Skindex-29, Dermatology Life Quality Index, Psoriasis Disability Index and Medical Outcome Study Short Form 36 in patients with mild to severe psoriasis.Quality of life instruments in psoriasis clinical trials.DLQI as a major criterion for introduction of systemic agents in patients with mild psoriasis.The impact of biologic agents on health-related quality of life outcomes in patients with psoriasis.Elevated prevalence of Type D (distressed) personality in moderate to severe psoriasis is associated with mood status and quality of life impairment: a comparative pilot study.Pictorial representation of illness and self measure (PRISM): an effective tool to assess the burden of psoriasis.SF-36 healty survey on psoriasis quality-of-life: a study of 414 Taiwanese patients.
P2860
Q24188109-7EBB8ED7-6C24-4BA3-8877-4C0CE689D65BQ26744346-0879AAF5-D66C-4083-A815-3BD52D62A3E0Q30584293-63C8A1F3-429C-4CC2-904F-34E7B7680F15Q33785083-5411095A-080E-413D-BA43-FD4A67F40119Q34996214-05C78587-AF4D-4F01-B1F9-349931AB0C10Q34997467-712AFF49-B81B-4A3B-ABAA-7B32695EFAF3Q35899890-65C70944-59FA-4E67-B40D-B20EB7AC6E37Q36005460-B4067F32-13CD-4C04-B64B-D9ED2A631DD8Q36033361-971BB4B9-7CA0-4E9F-8F6D-0BCD998DA9ACQ36281548-51B6CBEF-8858-4E43-940E-771BA0B575BAQ36299430-CD2C0211-FA6A-4E30-96FD-AAB72340DA36Q37233759-77241BA3-6373-47E7-A223-11B9E3B4DF85Q37638892-2E5D30CD-202C-46BB-9F61-0811BD060C6CQ37896160-2B65E869-638E-4FCD-B580-301CC99C2B6BQ37998915-3B49B4DF-0199-499C-8202-4490B5D1F837Q37998917-D5ACE804-981D-414D-A0F9-44CA6DBAD4C1Q38027577-B7537266-FACC-4277-AFD1-0C20BCEB1FACQ38044995-BE4C19DE-F9BA-49C1-BF2E-BB2CE9CE1CD4Q38075023-C27923D8-9167-4DA0-89B6-5058C64B1875Q38265085-50C026F3-D953-4ABC-91CE-A2640B4AD5E6Q38354062-BEE1F751-2299-4D55-8EB1-228C03050CACQ38712213-673614C3-3696-41BB-8E68-E7324E6234AEQ38921748-DEFD9F8F-29D6-4A25-BC87-B6592491E664Q39078782-1B46A70A-4781-460F-9FDD-5498CACFB34BQ39274236-283EA2B6-F68D-47B0-8F8A-56EE65C2D969Q39371919-48E9BF78-FEFF-4FCA-AC5B-89D6CD40A5ABQ39546109-8CB7F75B-8B4A-47F3-9E99-BCC497C9BC60Q40209526-2A62355D-FE10-4A1D-9ACE-E6962528075FQ40361911-0B5D9CF6-7C7F-42E1-BDFC-049690F4274CQ40419030-86598D70-081E-4CD1-A699-FB3158937834Q41008261-FEA0D0F6-2413-4D98-BC6E-C3E65C0D36DCQ41540546-81AE30A2-D747-4955-8F64-E51A7F9E42FBQ43866712-E9A7360F-A5E2-443F-9643-87BC0C0E2D3EQ45918198-292F470A-C5C6-40FE-BD1F-B2C190DBCEA8Q47570071-3CE3AA91-A0F8-4D51-A98D-CE911D74C5F4Q47637078-5C3747FA-D315-4F77-9C31-3BC4F78E4E88Q47644680-3D3DC5BD-DBEE-4035-995F-C5F59BC754B4Q47754478-DBDD0763-5179-4B2F-AF0D-F9A4D3F636D7Q47974732-39811E5C-3271-47B6-B0A1-390D67147DB2Q48053421-C9D34ED6-6066-4A32-901F-288324BEA055
P2860
What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
What are the best outcome meas ...... atic review of the literature.
@ast
What are the best outcome meas ...... atic review of the literature.
@en
What are the best outcome meas ...... atic review of the literature.
@nl
type
label
What are the best outcome meas ...... atic review of the literature.
@ast
What are the best outcome meas ...... atic review of the literature.
@en
What are the best outcome meas ...... atic review of the literature.
@nl
prefLabel
What are the best outcome meas ...... atic review of the literature.
@ast
What are the best outcome meas ...... atic review of the literature.
@en
What are the best outcome meas ...... atic review of the literature.
@nl
P2093
P1476
What are the best outcome meas ...... atic review of the literature.
@en
P2093
J-P Ortonne
M Le Maitre
M-A Richard-Lallemand
P-A Gourraud
P356
10.1111/J.1468-3083.2009.03563.X
P478
24 Suppl 2
P577
2010-04-01T00:00:00Z